Matthew R. Steensma

NF1 splicing reprograms ERα signaling to promote luminal breast cancer progression

This paper identifies an alternatively spliced NF1 isoform, NLS SE, that promotes luminal breast cancer progression by disrupting nuclear neurofibromin function and reprogramming ER signaling toward post-transcriptional regulation.

YAP signaling promotes resistance to MEK and AKT inhibition in NF1-related MPNSTs

This study identifies YAP signaling as a driver of resistance to MEK and AKT inhibitors in NF1-related MPNSTs using preclinical models and spatial transcriptomics.

Engineering ERα degraders with pleiotropic ubiquitin ligase ligands maximizes therapeutic efficacy by co-opting distinct effector ligases

This study evaluates bifunctional ER degraders with different ubiquitin ligase ligands, finding that pan-IAP antagonists enhance ER degradation and induce TNF-dependent cell death more effectively than existing therapies.

Distinctive epigenomic alterations in NF1-deficient cutaneous and plexiform neurofibromas drive differential MKK/P38 signaling

This study identifies epigenetic differences between cutaneous and plexiform neurofibromas that drive distinct RAS/MKK/P38 signaling and clinical behavior.

Oncogenic RAS-MET signal interactions are modulated by P53 status in NF1-related MPNSTs

This study shows that P53 status modulates the response to MET and MEK inhibition in NF1-related MPNSTs, with P53 wild-type tumors showing greater suppression of RAS/MAPK and PI3K/AKT activation.

Genomic MET amplification occurs early in NF1-related malignant peripheral nerve sheath tumor (MPNST) progression and is a potent therapeutic target

This study identifies early MET amplification in NF1-related MPNST progression and shows MET inhibition effectively targets these tumors.